On Tuesday, Shares of Micron Technology, Inc. (NASDAQ:MU), lost -2.22% to $27.79.
Micron Technology, declared a new addition to its expansive portfolio of flash storage products, providing a purpose-built solution for cost-sensitive consumer applications seeking high performance and reliability. The new TLC NAND is built on their 16-nanometer (nm) process and delivers a balanced set of features for applications like USB drives and consumer solid state drives. The market appetite for TLC is projected to be strong throughout 2015, constituting almost half of the total NAND gigabytes shipped.
Micron`s 16nm process-recognized by TechInsights as the Most Innovative Memory Device and 2014 Semiconductor of the Year-is a mature and proven storage technology, making it an excellent foundation for a reliable TLC design. TLC, or triple-level cell, is a technology that fits three bits in every flash data cell, creating greater cost and size efficiency.
Customers of the technology will benefit from Micron`s extensive design support team, who act as trusted advisors to ensure smooth qualification and optimal end-solution performance. Key flash customers and ecosystem partners worldwide have already begun working to integrate this new NAND with their latest designs, ensuring quick adoption in end applications.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of Vical Incorporated (NASDAQ:VICL), inclined 11.36% to $0.98, during its last trading session.
Vical Incorporated, declared the completion of enrollment in a Phase 2 trial of its therapeutic cytomegalovirus (CMV) vaccine in solid organ transplant recipients. ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma Inc. (TOKYO:4503), which is conducting the Phase 2 trial and an ongoing pivotal Phase 3 trial in hematopoietic stem cell transplant recipients.
Enrollment in the Phase 2 trial was accomplished almost a year ahead of plan. A total of 150 kidney transplant recipients were enrolled, surpassing the original enrollment target of 140. The trial has enrolled subjects at about 80 centers in North America, Europe and Australia.
The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of ASP0113 in CMV-seronegative kidney transplant recipients receiving an organ from a CMV-seropositive donor (D+/R-). The primary endpoint will evaluate efficacy of ASP0113 with 100 days of valganciclovir — contrast to placebo with 100 days of valganciclovir — in reducing the incidence of CMV viremia over a period of one year following the first vaccination. Secondary endpoints comprise incidence of CMV disease, overall survival, and others. Topline trial results are predictable in the second half of 2016.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates comprise CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which accomplished preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission.
At the end of Tuesday’s trade, Shares of Exelon Corporation (NYSE:EXC), lost -0.76% to $33.73.
The Delaware Public Service Commission (PSC) recently issued an order approving the merger between Exelon Corporation, and Pepco Holdings Inc. (POM) upon the terms set forth in the parties’ application, as amended by the Amended Settlement Agreement filed with the PSC on April 7, 2015. This action follows the Commission’s deliberations on May 19, 2015, when the Commission voted to approve the Amended Settlement Agreement. Today’s order approves the merger and authorizes the consummation of the merger. A further order with the PSC’s specific grounds for approval will follow at a later date. The companies declared their projected merger on April 30, 2014, and presented their application to merge to the PSC on June 18, 2014.
The Amended Settlement Agreement was filed by Exelon, PHI and Delmarva Power on April 7, 2015, and signed by PSC Staff, the Delaware Public Advocate, the Department of Natural Resources and Environmental Control (DNREC), the Delaware Sustainable Energy Utility, the Mid-Atlantic Renewable Energy Coalition and the Clean Air Council. The terms provide more than $42 million in direct benefits, deliver noteworthy economic benefits to Delaware and Delmarva Power customers, promote energy efficiency, enhance reliability, support workforce development and promote the public interest.
The merger will bring together Exelon’s three electric and gas utilities – BGE, ComEd and PECO – and Pepco Holdings’ (PHI) three electric and gas utilities – Atlantic City Electric (ACE), Delmarva Power and Pepco – to create the leading mid-Atlantic electric and gas utility.
The merger still requires approval by the Public Service Commission of the District of Columbia.
The transaction was approved by the Maryland Public Service Commission in May, the New Jersey Board of Public Utilities in February, the Federal Energy Regulatory Commission in November, the Virginia State Corporation Commission in October and the PHI stockholders in September.
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Finally, American Express Company (NYSE:AXP), ended its last trade with 0.65% surge, and closed at $79.99.
American Express Company, is now offering Premier Rewards Gold Card Members new dining and travel benefits, adding more value to one of its most iconic and popular cards. New and existing Card Members now receive:
- 2x Membership Rewards® points at U.S. restaurants.
- $100 airline fee credit at one airline for incidental charges such as baggage fees.
- Personalized travel service with access to practiced travel counselors who can assist with everything from a basic flight to the most complicated itinerary.
- No foreign transaction fees from American Express.
- In addition to the added benefits mentioned above, Premier Rewards Gold Card Members continue to receive:
- 3x Membership Rewards points on flights purchased directly from airlines
- 2x Membership Rewards points for purchases at U.S. gas stations and U.S. supermarkets
- Access to The Hotel Collection, a roster of more than 350 exceptional properties around the world; Card Members are eligible for a $75 hotel amenities credit and a room upgrade if accessible.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide. The company operates through four segments: U.S. Card Services, International Card Services, Global Commercial Services, and Global Network & Merchant Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
